Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
uniQure’s gene-therapy filings aren’t light reading. Between pages of clinical data, royalty accounting for Hemgenix and detailed manufacturing disclosures, even seasoned biotech investors can miss what moves the stock. If you’ve ever typed “How do I read uniQure’s 10-K?” or searched for “uniQure insider trading Form 4 transactions,” you know the challenge.
Stock Titan turns those 200-page documents into clear, actionable insights. Our AI-powered summaries explain complex sections of the uniQure annual report 10-K simplified, flag trial milestones in each uniQure quarterly earnings report 10-Q filing, and translate every uniQure 8-K material events explained into plain English within minutes of EDGAR release. Need management sentiment? Real-time alerts surface uniQure executive stock transactions Form 4 so you can track buying or selling before the market reacts. From cash-burn analysis to partnership revenue recognition, the platform answers the natural question, “What does uniQure report in their SEC filings?”
You’ll also find one-click access to the company’s proxy statement for executive compensation, shelf registrations that fund future trials, and historical uniQure Form 4 insider transactions real-time feeds. Whether you’re comparing quarter-over-quarter pipeline spend, monitoring dilution risk, or simply looking for a concise uniQure earnings report filing analysis, Stock Titan’s expert layers and AI context keep you ahead without wading through jargon. Understanding uniQure SEC documents with AI means informed decisions, faster.
uniQure N.V. (QURE) filed a prospectus supplement for an “at-the-market” equity program of up to $200 million in ordinary shares, par €0.05, to be sold from time to time through Leerink Partners LLC.
Leerink will act as sales agent and is entitled to a commission of up to 3 % of gross proceeds and will be treated as an underwriter. Shares will be issued on The Nasdaq Global Select Market at prevailing prices. Using the 25-Jul-2025 close of $15.11, a full draw would add roughly 13.24 m shares, lifting total shares outstanding to 68.10 m.
- Post-offering pro-forma net tangible book value rises from −$2.08 to $1.17 per share, creating immediate dilution of $13.94 for new investors.
- Proceeds will fund the potential U.S. launch of lead gene-therapy AMT-130, advance multiple clinical programs (AMT-260, AMT-191, AMT-162), support business development and general corporate needs.
- Risk highlights: discretionary use of funds, potential share-price pressure from sales, extensive outstanding equity awards, PFIC classification for 2024, no dividend policy and share-price volatility.
There is no minimum sale requirement and proceeds are not escrowed, giving the company flexibility but leaving investors uncertain about timing and pricing of dilution.
Director Jeremy P. Springhorn of uniQure reported a sale of 2,112 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). Following the transaction, Springhorn retains direct ownership of 37,694 shares.
Key details of the transaction:
- The sale was non-discretionary, executed automatically to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was conducted under automatic sale instructions included in the Restricted Share Unit Agreement
- The Form 4 was filed by Christian Klemt as attorney-in-fact
This transaction appears to be a routine share sale for tax purposes rather than a strategic investment decision by the director.
uniQure Director Leonard E. Post reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated withholding taxes following the vesting of restricted share units, according to automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Post continues to directly own 29,937 ordinary shares of uniQure. The sale was conducted through automatic sale instructions and was not a discretionary trade by the reporting person.
- Transaction Type: Non-discretionary sale (tax withholding)
- Total Transaction Value: Approximately $30,518
- Ownership Form: Direct
- Filing was signed by Christian Klemt as Attorney-in-Fact
Director Jack Kaye of uniQure reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). Following the transaction, Kaye retains direct ownership of 20,439 shares.
Key transaction details:
- The sale was automatically executed to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was made pursuant to automatic sale instructions in the Restricted Share Unit Agreement
- The sale was non-discretionary and not a voluntary trade by the director
- Form was filed through an attorney-in-fact on June 24, 2025
uniQure director Rachelle Suzanne Jacques reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50).
Key details of the transaction:
- The sale was automatically executed to cover estimated withholding taxes upon vesting of restricted share units
- Transaction was made according to automatic sale instructions in the Restricted Share Unit Agreement
- Following the transaction, Jacques continues to hold 28,346 ordinary shares directly
- The filing was signed by Christian Klemt as attorney-in-fact on June 24, 2025
This transaction represents a routine tax-related share sale rather than a discretionary trading decision by the insider.
uniQure Director Robert Gut reported a non-discretionary sale of 3,336 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed automatically to cover estimated tax withholdings following the vesting of restricted share units.
Following the reported transaction, Gut maintains direct beneficial ownership of 56,879 ordinary shares. The sale was conducted pursuant to automatic sale instructions included in the Restricted Share Unit Agreement and was not a discretionary trade by the reporting person.
- Transaction type: Non-discretionary sale (S)
- Purpose: Tax withholding coverage
- Execution: Automatic upon RSU vesting
- Filing relationship: Director
FAQ
What is the current stock price of Uniqure (QURE)?
What is the market cap of Uniqure (QURE)?
